FAAH and complex regional pain syndrome: Current studies indicate that the FAAH inhibitor URB597 reduces the nociceptive response caused by inflammatory and neuropathic pain in CRPS via systemic or intrathecal administration and that these pain-relieving effects can be blocked by cannabinoid receptor antagonists [26,27].